Clinical, biochemical, and hematological evolution according to the dosing group.

<p>Median values are shown for the following parameters: temperature (Temp), weight, hemoglobin (HB), lymphocyte count (LYMP), monocyte count (MONO), neutrophil count (NEUTRO), platelets (PLQ) (giga/l [G/L]), alanine aminotransferase (ALT), and C-reactive protein (CRP). Black: untreated; blue: 150 mg/kg BID; red: 180 mg/kg BID. More parameters are available in <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1002535#pmed.1002535.s002" target="_blank">S2 Fig</a>. Given the limited number of data available, animals treated with 100 mg/kg BID are not represented.</p

Survival according to the dosing group.

<p>(A) Study design; (B) survival curves.</p

Evolution of the transition/transversion ratio overtime.

<p>Black: untreated; green: 100 mg/kg BID; blue: 150 mg/kg BID; red: 180 mg/kg BID.</p

Virological and pharmacological results according to the dosing group.

<p>(A) Blood molecular viral load; (B) blood virus titer; (C) favipiravir trough concentrations. EBOV, Ebola virus; ffu, focus-forming units.</p

Drug concentrations observed in nonhuman primates compared to what was observed in humans in the JIKI trial [12].

<p>Drug concentrations observed in nonhuman primates compared to what was observed in humans in the JIKI trial [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1002535#pmed.1002535.ref012" target="_blank">12</a>].</p

Association between average trough drug concentration until D7 and survival and virological response at D7.

<p>(A) Survival time according to molecular viral load at D7; (B) molecular viral load at D7 according to favipiravir average trough drug concentration until D7; (C) viral titer at D7 according to the average trough drug concentration until D7 (data missing for 1 animal in the 180 mg/kg BID group). The black solid line indicates the best fit to the data (see <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1002535#sec009" target="_blank">Methods</a>). Black: untreated; green: 100 mg/kg BID; blue: 150 mg/kg BID; red: 180 mg/kg BID. EBOV, Ebola virus; ffu, focus-forming units.</p

Observed trough concentrations of favipiravir at Day-2 and Day-4 in patients who died and those who survived according to the initial baseline EBOV viral load.

<p>Observed trough concentrations of favipiravir at Day-2 and Day-4 in patients who died and those who survived according to the initial baseline EBOV viral load.</p

Observed and adjusted predicted (from the pharmacokinetic model provided by the manufacturer) trough concentrations of favipiravir at Day-2 and Day-4 in the 66 patients included in the PK analysis of the JIKI trial.

<p>Observed and adjusted predicted (from the pharmacokinetic model provided by the manufacturer) trough concentrations of favipiravir at Day-2 and Day-4 in the 66 patients included in the PK analysis of the JIKI trial.</p

Observed trough concentrations (y-axis) versus predicted trough concentrations (x-axis) at Day-2 (left, n = 44 observations) and Day-4 (right, n = 50) after treatment initiation.

<p>Red points represent concentrations measured in patients who died during the trial, green points represent concentrations measured in those who survived.</p

Flowchart of the patients included in the PK analysis of the JIKI trial

<p>Flowchart of the patients included in the PK analysis of the JIKI trial</p